Explore Stanford technologies available for licensing:

Stanford researchers have developed the Broadly Usable Multi-Pass Engineered Receptor (BUMPER) architecture, a novel protein engineering platform for assembling stable, multifunctional cell surface receptors.

Stanford researchers have developed a novel mutant IL-9 receptor (IL9R) that significantly enhances the in vivo engraftment, expansion, and anti-tumor activity of adoptively transferred T cells.

Researchers at Stanford have developed a clinically applicable method of bone marrow conditioning for stem cell transplantation or treatment of hematologic malignancies.

Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.

Stanford researchers have developed the first ex vivo bone marrow niche capable of sustaining normal and diseased hematopoietic cells long-term.

In 2021, almost 200,000 patients were diagnosed with leukemia and other blood and immune diseases in the US.

Disease Indication Oncology, hematological cancers, breast cancer, solid tumors

Drug Format Cell therapy

Drug Class Best-in-class

Target CD19, HER2, B7-H3, GPC2 and all other tumor antigens